■ 学術雑誌
|
原著
|
|
1.
|
Tetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki, Yukiko Kajiwara, Mitsugu Yamamoto, Ken-ichi Watanabe, Masami Tsukabe, Fumie Fujisawa, Shigenori E. Nagai, Nobuhiro Shibata, Chiya Oshiro, Hiroko Bando, Nobuyuki Tsunoda, Kazuhiko Yamagami, Kei Koizumi, Masahiro Takada, Naoko Toriguchi, Nobuyuki Sekine, Tsutomu Kawaguchi, Shigehira Saji, Yasuaki Sagara, Satoshi Morita, Norikazu Masuda：
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
Breast cancer
32
(4)
：841
-856
, 2025
|
|
2.
|
Tetsuhiro Yoshinami, Nobuhiro Shibata, Kentaro Tamaki, Kentaro Ishimaru, Satoru Ito, Tomoyuki Nukada, Shinji Ohno：
Real-world evidence of febrile neutropenia-related hospitalization on patients with perioperative chemotherapy for early breast cancer in Japan.
Breast cancer
32
(4)
：857
-866
, 2025
|
|
3.
|
Kentaro Sawada, Riu Yamashita, Shunsuke A Sakai, Satoshi Horasawa, Ayumu Yoshikawa, Takao Fujisawa, Shigenori Kadowaki, Ken Kato, Makoto Ueno, Eiji Oki, Yoshito Komatsu, Tatsuyuki Chiyoda, Yosuke Horita, Hisateru Yasui, Tadamichi Denda, Hironaga Satake, Taito Esaki, Taroh Satoh, Naoki Takahashi, Kentaro Yamazaki, Nobuhisa Matsuhashi, Tomohiro Nishina, Hiroyuki Takeda, Koushiro Ohtsubo, Takashi Ohta, Akihito Tsuji, Masahiro Goto, Takeshi Kato, Hideaki Bando, Katsuya Tsuchihara, Yoshiaki Nakamura, Takayuki Yoshino：
Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study.
Cancer research communications
5
(5)
：857
-870
, 2025
|
|
4.
|
Tadayoshi Hashimoto, Naoko Iida, Yoshiaki Nakamura, Norio Nonomura, Chigusa Morizane, Hiroji Iwata, Susumu Okano, Wataru Yamagami, Naoya Yamazaki, Shigenori Kadowaki, Makoto Ueno, Shogen Boku, Eiji Oki, Yoshito Komatsu, Satoshi Yuki, Akitaka Makiyama, Takatsugu Ogata, Naoki Takahashi, Naohiro Okano, Tomohiro Nishina, Naoya Sakamoto, Takeshi Kuwata, Riu Yamashita, Taro Shibuki, Mitsuho Imai, Takao Fujisawa, Hideaki Bando, Kohei Shitara, Takayuki Yoshino：
Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR-SCREEN-2 Study.
Cancer science
116
(8)
：2218
-2231
, 2025
|
|
5.
|
Akihito Kawazoe, Kensei Yamaguchi, Tetsuya Hamaguchi, Yukiya Narita, Shogen Boku, Takashi Oshima, Hiroki Hara, Yasuo Hamamoto, Kenji Ishido, Taito Esaki, Hisashi Hosaka, Hirofumi Yasui, Keisuke Koeda, Tomohiro Nishina, Yasushi Tsuji, Takeo Fukagawa, Masahiro Goto, Eiji Oki, Naotoshi Sugimoto, Hiroshi Matsuoka, Fumiharu Yokoyama, Tomoko Yoshida, Kazuo Yoshida, Yoshiaki Oshima, Satoru Iwasa：
ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.
Cancer science
116
(9)
：2523
-2536
, 2025
|
|
6.
|
Shogen Boku, Tatsuki Ikoma, Tomoyo Yasuda, Nobuhiro Shibata, Tomofumi Sakagami, Kensuke Suzuki, Takuo Fujisawa, Hiroshi Iwai, Masashi Kanai：
Relationship between the effectiveness of pembrolizumab monotherapy and ABO blood type in recurrent and metastatic squamous cell carcinoma of the head and neck.
Discover oncology
16
(1)
：1302
, 2025
|
|
7.
|
Shogen Boku, Hironaga Satake, Seiichiro Mitani, Kiyoshi Maeda, Toshihiro Kudo, Toshifumi Yamaguchi, Tatsuya Takagi, Hisato Kawakami：
A placebo-controlled study of the doses and efficacy of Lentinula edodes mycelia for oxaliplatin-induced peripheral neuropathy in colorectal cancer.
Frontiers in oncology
15
：1577848
, 2025
|
|
8.
|
Hisateru Yasui, Masaki Aizawa, Kensei Yamaguchi, Akihito Kawazoe, Hiroki Hara, Masahiro Tsuda, Hirokazu Shoji, Naotoshi Sugimoto, Nobuhiro Shibata, Kenji Amagai, Yasuhiro Choda, Shiro Iwagami, Taito Esaki, Shigenori Kadowaki, Shinichi Shiratori, Shirong Han, Sonal Bordia, Kohei Shitara：
First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study.
International journal of clinical oncology
30
(10)
：2003
-2011
, 2025
|
|
9.
|
Fujisawa T, Nakamura Y, Bando H, Morizane C, Ikeda M, Nonomura N, Matsubara
N, Iwata H, Naito Y, Okano S, Aoki D, Harano K, Yamazaki N, Namikawa K, Ueno M,
Kadowaki S, Oki E, Kato K, Komatsu Y, Satoh T, Esaki T, Denda T, Hamaguchi T,
Yamazaki K, Matsuhashi N, Yasui H, Satake H, Nishina T, Takahashi N, Goto M,
Sunakawa Y, Kato T, Otsuka T, Abutani H, Tukachinsky H, Lee JK, Oxnard GR,
Kuramoto N, Horasawa S, Sakamoto Y, Taniguchi H, Yoshino T.：
Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study.
JCO Precision Oncology
9
：e2400283
, 2025
|
|
10.
|
Daisuke Sakai, Shigenori Kadowaki, Ryohei Kawabata, Hiroki Hara, Hironaga Satake, Masazumi Takahashi, Atsushi Takeno, Hiroo Imai, Keiko Minashi, Takeshi Kawakami, Shogen Boku, Jin Matsuyama, Yasuhiro Sakamoto, Kentaro Sawada, Masato Kataoka, Hisato Kawakami, Toshio Shimokawa, Narikazu Boku, Taroh Satoh：
Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
43
(19)
：2196
-2207
, 2025
|
|
11.
|
Okazawa-Sakai M, Sakai SA, Hyodo I, Horasawa S, Sawada K, Fujisawa T,
Yamamoto Y, Boku S, Hayasaki Y, Isobe M, Shintani D, Hasegawa K, Egawa-Takata T,
Ito K, Ihira K, Watari H, Takehara K, Yagi H, Kato K, Chiyoda T, Harano K,
Nakamura Y, Yamashita R, Yoshino T, Aoki D.：
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.
Journal of gynecologic oncology
36
(3)
：e38
, 2025
|
|
12.
|
Toshihiko Matsumoto, Tatsuki Ikoma, Chinatsu Makiyama, Tomoyo Yasuda, Shogen Boku, Akio Nakasya, Nobuhiro Shibata, Hiroki Nagai, Takao Tsuduki, Yusuke Matsumoto, Hisateru Yasui, Reiji Higashi, Akitoshi Sasamoto, Hironaga Satake, Kentaro Inoue, Masashi Kanai, Makoto Yamasaki：
Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab.
Scientific reports
15
(1)
：28841
, 2025
|
|
13.
|
Nobuhiro Shibata, Hiroshi Kuwazawa, Tomoharu Yasukawa, Manabu Iwabuchi, Shigehira Saji：
The safety and effectiveness of pegfilgrastim to reduce cancer chemotherapy-induced febrile neutropenia in real-world practice in Japan: a post-marketing surveillance study.
Supportive care in cancer
in press
, 2025
|
|
その他
|
|
1.
|
栗岡 勇輔, 坂本 秀男, 朴 将源, 竹村 幸敏, 佐竹 悠良：
大腸内視鏡生検標本を用いた患者由来腫瘍スフェロイドモデルの確立.
日本大腸肛門病学会雑誌
７８
(２)
：１０１
-１０１
, 2025
|
|
■ 学会発表
|
全国規模の学会
|
|
1.
|
柴田伸弘：
CDK４／６阻害薬のエビデンスとガイドライン総点検.
第23回日本乳癌学会九州地方会 イブニングセミナー,
福岡,
2025/09
|
|
2.
|
◎遠藤香代子, 金森史佳, 梅嵜乃斗香, 平井千惠, 太治智愛, 矢内洋次, 柴田信弘, 木川雄一郎, 髙田正泰：
当院における男性乳癌の検討.
第33回日本乳癌学会学術総会,
東京,
2025/07
|
|
3.
|
◎金森史佳, 木川雄一郎, 梅嵜乃斗香, 平井千恵, 遠藤佳代子, 太治智愛, 矢内洋次, 柴田伸弘, 高田正泰：
術前化学療法としてPembrolizumab投与中に免疫関連有害事象である腎障害をきたし血液透析導入となった1例.
第33回日本乳癌学会学術総会,
東京,
2025/07
|
|
4.
|
◎柴田伸弘, 松井千亜希, 平井千惠, 太治智愛, 多田真奈美, 矢内洋次, 木川雄一郎, 杉江知治, 髙田正泰：
PD-L1陽性進行・再発TNBCにおけるAtezolizumabメンテナンス治療の検討.
第33回日本乳癌学会学術総会,
東京,
2025/07
|
|
5.
|
◎田根香織, 三木万由子, 尾上琢磨, 木川雄一郎, 柴田伸弘, 山下祐司, 國久智成, 馬場基, 森田翠, 岩朝勤, 吉波哲大, 太治智愛, 木村光誠, 渡邉諭美, 伊藤亜樹, 高橋侑子, 橋本一樹, 岡本明子, 尾崎由記範, 松本光史：
施設と地域を越えた、次世代を牽引する若手乳腺診療医の育成～KIRARIのこれまでとこれから～.
第33回日本乳癌学会学術総会,
東京,
2025/07
|
|
6.
|
◎梅嵜乃斗香, 平井千惠, 多田真奈美, 遠藤香代子, 柴田伸弘, 矢内洋次, 木川雄一郎, 高田正泰：
ペムブロリズマブ投与後に重症肝障害を認め、、ステロイドパルス+血漿交換を施行したStaegeIIIC乳癌の1例.
第33回日本乳癌学会学術総会,
東京,
2025/07
|
|
7.
|
◎矢内洋次, 木村香里, 島田咲, 金森史佳, 平井千惠, 太治智愛, 佐藤智佳, 遠藤香代子, 柴田伸弘, 木川雄一郎, 玉置知子, 髙田正泰：
BRCA遺伝学的検査によりinconclusiveと診断された症例の検討.
第33回日本乳癌学会学術総会,
東京,
2025/07
|
|
8.
|
◎安田知代, 生駒龍興, 山本宜之, 張野誉史, 朴 将源, 井上健太郎, 山﨑 誠：
切除不能／再発食道癌対するレジメン選択とConversion手術の可否に関する解析.
第79回日本食道学会学術集会,
京都,
2025/06
|
|
その他
|
|
1.
|
柴田伸弘：
PassionがつなぐEvidenceとExperience－転移・再発トリプルネガティブ乳癌治療、日本一の治療経験を次の臨床へ伝えるためにー.
第33回日本乳癌学会学術総会 ランチョンセミナー,
東京,
2025/07
|
|
